257 results about "Vascular problem" patented technology

Systems and methods are disclosed for evaluating a patient with vascular disease. One method includes receiving patient-specific data regarding a geometry of the patient's vasculature; creating an anatomic model representing at least a portion of a location of disease in the patient's vasculature based on the received patient-specific data; identifying one or more changes in geometry of the anatomic model based on a modeled progression or regression of disease at the location; calculating one or more values of a blood flow characteristic within the patient's vasculature using a computational model based on the identified one or more changes in geometry of the anatomic model; and generating an electronic graphical display of a relationship between the one or more values of the calculated blood flow characteristic and the identified one or more changes in geometry of the anatomic model.

Systems and methods are disclosed for evaluating a patient with vascular disease. One method includes receiving patient-specific data regarding a geometry of the patient's vasculature; creating an anatomic model representing at least a portion of a location of disease in the patient's vasculature based on the received patient-specific data; identifying one or more changes in geometry of the anatomic model based on a modeled progression or regression of disease at the location; calculating one or more values of a blood flow characteristic within the patient's vasculature using a computational model based on the identified one or more changes in geometry of the anatomic model; and generating an electronic graphical display of a relationship between the one or more values of the calculated blood flow characteristic and the identified one or more changes in geometry of the anatomic model.

A compound, as shown in Formula I, is a multi-heterocyclic compound. It has been verified that the compound provided by this invention integrates a novel compound targeting the calcitonin gene-related peptide (CGRP) based on ephedrine. Upon contact with the skin, due to photoactivated cell biological function regulation and the blocking effect of the multi-heterocyclic compound I structure on serotonin receptors, it achieves therapeutic effects on cutaneous vascular malformations and telangiectasia, improves the effectiveness of phototherapy in improving chronic cutaneous vascular diseases, and promotes skin wound healing.

The invention relates to lauroyl cilostazol as well as a preparation method and application thereof. Wherein the lauroyl cilostazol is sterile, and preferably, the lauroyl cilostazol is a crystal. The invention further provides application of the lauroyl cilostazol in preparing medicines for treating cerebral infarction, cerebrovascular diseases, atherosclerosis, diabetic complications, peripheral vascular diseases, Reynolds diseases, intermittent claudication, ischemic heart diseases and acute coronary syndromes. The lauroyl cilostazol has the remarkable long-acting characteristic.

The invention discloses a pulmonary vascular endothelial barrier injury model and a construction method and application thereof, and relates to the technical field of biologication.The construction method of the pulmonary vascular endothelial barrier injury model comprises the following steps that a healthy mouse is adaptively fed for one week and then anesthetized with a medicine, oncostatin M recombinant protein is pretreated and then instilled into the lung of the mouse through an airway, and then the mouse is subjected to tumor cell apoptosis; obtaining a pulmonary vascular endothelial barrier injury model; the invention further discloses a pulmonary vascular endothelial barrier injury model, application of the model in preparation of a pulmonary vascular disease research model and application of the model in preparation of drugs for treating pulmonary vascular diseases. According to the pulmonary vascular endothelial barrier injury model as well as the construction method and the application thereof provided by the invention, the oncostatin M protein is combined with an oncostatin M receptor type II on an endothelial cell to activate a downstream signal channel, so that the endothelial barrier is damaged, a clear target spot is provided for the endothelial barrier injury, and a pulmonary injury mechanism can be deeply discussed.

The invention discloses a post-stroke depression risk prediction system based on cerebral small vascular diseases and inflammatory markers, and relates to the technical field of computer-aided engineering, the post-stroke depression risk prediction system comprises: a data acquisition module acquires CSVD image data, serum inflammatory markers and clinical baseline information; the data preprocessing module processes image denoising registration, fills up marker missing values and encodes clinical information; the CSVD feature extraction module extracts image omics features and quantifies severity; the inflammation marker module calculates statistical characteristics and inflammation intensity; the multi-dimensional fusion module integrates features and eliminates redundancy; the risk prediction module is trained by using an improved attention CNN-LSTM model; the result output module visualizes risk and intervention suggestions; the model dynamic optimization module updates parameters by incremental learning. According to the method, multi-source key data are integrated, the prediction accuracy and generalization ability are improved, clinical interpretation and dynamic adaptability are achieved, early recognition of post-stroke depression is assisted, and patient prognosis is improved.

The invention relates to the technical field of medical image processing, and discloses an adversarial generative network model for three-dimensional reconstruction of a brain cell-level vascular network. The model comprises a three-dimensional blood vessel feature extraction module, a dynamic attention generator, a multi-scale discriminator and the like. Characteristics are obtained through multi-modal medical image data (magnetic resonance angiography and confocal microscope scanning data), and high-precision vascular network three-dimensional reconstruction is realized by utilizing cooperative work of all the modules. The dynamic attention generator calculates the topological connection probability of the vascular branches, and the multi-scale discriminator globally and locally evaluates the reconstruction result. Meanwhile, model training is optimized through an adversarial training controller, and the blood vessel network is perfected through a capillary network completion module. According to the method, the advantages of multi-modal data are effectively fused, the reconstruction precision is improved, and powerful support is provided for research and diagnosis of brain vascular diseases.

The invention provides a multi-modal AI diagnosis and risk grading system, method and device suitable for vascular diseases, a medium and a program product, and provides an innovative method for cardiovascular diagnosis of old people by combining hemodynamics and structural indexes and utilizing a multi-modal deep learning framework. According to the method, the diagnosis accuracy is improved, and the prediction capability is enhanced through operable risk scoring. The method is unique in that double diagnosis of functions and structures is integrated, and compared with a traditional method focusing on single diagnosis, the method provides more comprehensive cardiovascular health assessment. Besides, the system has high applicability and expandability, can be integrated with clinical and wearable equipment, and realizes real-time monitoring and risk assessment. In the future, the system can further enlarge the diagnosis range by incorporating data such as biomarkers and the like, and shows good future adaptability.

The invention relates to the technical field of blood vessel structure recognition, and discloses an automatic recognition method and system for an OCT image blood vessel structure, and the method comprises the steps: 1, blood vessel layer boundary feature extraction: extracting blood vessel layer boundary features, including geometric features and physical features, from an OCT image based on multi-scale Hessian matrix response, and forming a feature response graph; step 2, three-layer topological structure identification: constructing a topological relation of a blood vessel structure according to the feature response diagram, and extracting a nested annular structure; identifying and outputting a three-layer initial boundary coordinate point set and a structure score of an inner membrane, a middle membrane and an outer membrane of a blood vessel; and step 3, optimizing a blood vessel structure: accurately optimizing the initial boundary coordinate point set, detecting special cells in an optimized region, and generating a result report. According to the method, full-automatic recognition of the OCT blood vessel structure is achieved, reliability, accuracy and interpretability of a recognition result are ensured, and standardization and unification of vascular disease diagnosis are ensured.

Provided here are methods to prevent, inhibit or treat an autoimmune disease or a vascular or cardiovascular disorder in a mammal, comprising administering to the mammal a composition comprising an effective amount of isolated nucleic acid comprising a nucleotide sequence encoding WDFY3 / Alfy or a portion thereof, a nucleotide sequence comprising a WDFY3 / Alfy-specific long non-coding RNA (lncRNA) or a corresponding DNA sequence, a nucleotide sequence comprising a portion of a lncRNA WDFY3-AS2 or a corresponding DNA sequence, or isolated WDFY3 / Alfy or a portion thereof.

The invention discloses a medical image curative effect evaluation system based on artificial intelligence, and the system is characterized in that an acquisition module obtains a clinical vascular medical image, builds an image database according to the clinical vascular medical image, and builds a high-resolution vascular three-dimensional image according to the image data in the image database; a positioning recognition module receives the blood vessel three-dimensional image and inputs the blood vessel three-dimensional image into a trained blood vessel positioning model, and the blood vessel positioning model automatically recognizes the blood vessel position and level in the blood vessel three-dimensional image; the evaluation module is used for cutting and calculating the blood vessel three-dimensional image according to the recognized blood vessel position and level and a preset size, and evaluating whether the lesion position and lesion type of the blood vessel with blood vessel stenosis, blood vessel dilatation and blood vessel thickening occur or not according to a calculation result; the technical problem that the prior art is difficult to accurately evaluate the curative effect of vascular diseases is solved.

Systems and methods are disclosed for evaluating a patient with vascular disease. One method includes receiving patient-specific data regarding a geometry of the patient's vasculature; creating an anatomic model representing at least a portion of a location of disease in the patient's vasculature based on the received patient-specific data; identifying one or more changes in geometry of the anatomic model based on a modeled progression or regression of disease at the location; calculating one or more values of a blood flow characteristic within the patient's vasculature using a computational model based on the identified one or more changes in geometry of the anatomic model; and generating an electronic graphical display of a relationship between the one or more values of the calculated blood flow characteristic and the identified one or more changes in geometry of the anatomic model.

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I):and pharmaceutically acceptable salts thereof; wherein , R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The invention discloses a method for adjusting administration dosage according to adverse reaction risk based on a joint model, and is applied to the field of intelligent medical treatment. In the prior art, the relationship between the sirolimus steady-state valley concentration and the specific adverse reaction cannot be quantified, so that the defect of lack of accurate guidance for clinical medication is caused. Through systematic research, the method determines the individual target valley concentration range through a BKMR model for the first time, obtains individual pharmacokinetic parameters of a patient through a group pharmacokinetic model, and finally determines the medication time and the medication dosage of the patient through Bayesian negative feedback simulation, and the medication time and the medication dosage are used for adjusting a medication scheme. According to the invention, prospective risk prediction of adverse reactions of sirolimus is realized, the treatment safety of children with vascular diseases is remarkably improved, and long-term prognosis of patients is improved.

The invention is applied to the technical field of health-care products, and discloses a sea-buckthorn soft capsule, which comprises a capsule shell and a content, the capsule shell is composed of gelatin, water, glycerin and an auxiliary material, the auxiliary material is a preservative or a plasticizer, the content is composed of one of seabuckthorn seed oil or fruit oil, seabuckthorn powder and an auxiliary material, the auxiliary material is one of a suspending aid and an antioxidant or a mixture of the suspending aid and the antioxidant, the seabuckthorn powder is rich in flavone, and the auxiliary material is a mixture of the suspending aid and the antioxidant. The soft capsule has the effects of lowering lipid, softening blood vessels and preventing vascular diseases. According to the hippophae rhamnoides soft capsule, a product capsule shell is prepared from gelatin, water and glycerin according to a specific proportion, it can be guaranteed that the capsule shell has proper hardness and elasticity and is convenient to process and store, hippophae rhamnoides seed (fruit) oil and hippophae rhamnoides powder in the content are matched according to a reasonable proportion, the hippophae rhamnoides powder is rich in flavone, and the hippophae rhamnoides powder and the hippophae rhamnoides seed (fruit) oil act the effects of lowering lipid, softening blood vessels and preventing vascular diseases can be better exerted.

The application discloses a kind of nnUNet zebra fish juvenile whole brain vascular system segmentation methods based on autonomous data set training, it is related to high-resolution imaging technology, image processing and medical image segmentation field, the method makes full use of zebra fish live transparency and fluorescent label advantage, obtains high-resolution whole brain three-dimensional vascular image data, and constructs high-quality segmentation truth value database by semi-automatic segmentation and artificial correction, training is carried out using nnU-Net deep learning model, realize the three-dimensional automatic segmentation of zebra fish brain vascular system signal.The application method significantly improves the degree of automation and precision of image segmentation, effectively solves the problems of low efficiency, high artificial dependence and poor repeatability of traditional brain vascular segmentation.The method is suitable for large-scale high-throughput data processing, can provide efficient, standardized image processing scheme for zebra fish brain vascular development mechanism and brain vascular disease model research, and has wide application prospect.

The invention relates to the technical field of stem cells, and particularly discloses application of mesenchymal stem cells (MSC) in treatment of lower limb vein ischemia. According to the application, the SDF1-FGF2 fusion protein is used for pretreating human mesenchymal stem cells (hMSCs), and the cell activity, the blood flow recovery capacity and the anti-inflammatory effect of the hMSCs in a lower limb vein ischemia model can be remarkably improved through pretreatment. The hMSCs pretreated by SDF1-FGF2 are injected into the body of a venous ischemia model mouse, and compared with untreated cells, the hMSCs have better effects in the aspects of improving blood perfusion, reducing inflammatory response, recovering motor function and the like. The method provides an efficient stem cell treatment strategy for vascular diseases such as lower limb vein ischemia.

Compounds as inhibitors of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treatment of viral infections, neurodegenerative diseases, vascular diseases, or cancer.

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

Disclosed are flow diverters including a self-expanding tubular member comprising a plurality of expandable cells having interconnected zig-zag rings and diagonal struts. The tubular member has a constrained configuration having a first outer diameter of at least 1.0 mm sized for delivery using a flow diverter delivery system and an expanded configuration having a second outer diameter larger than the first outer diameter. Related devices, delivery systems, and methods of using the devices and delivery systems for treating disease, particularly intracranial and cerebral aneurysms by deploying implantable expandable devices, are provided.

Described herein are steroids of Formula (I):and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

A prediction system includes: a terminal; and a processor, communicatively coupled to the processor. The processor is configured to: acquire medical treatment information including images captured at at least one of before, during, immediately after, and after a predetermined period from treatment of a patient with a symptom of a vascular disease; classify a condition of the patient based on a classification image; learn the medical treatment information in association with the condition of the patient; and predict at least one of a treatment effect and a prognosis when treatment intervention is performed for the patient based on a learning result.

Systems and methods are disclosed for evaluating a patient with vascular disease. One method includes receiving patient-specific data regarding a geometry of the patient's vasculature; creating an anatomic model representing at least a portion of a location of disease in the patient's vasculature based on the received patient-specific data; identifying one or more changes in geometry of the anatomic model based on a modeled progression or regression of disease at the location; calculating one or more values of a blood flow characteristic within the patient's vasculature using a computational model based on the identified one or more changes in geometry of the anatomic model; and generating an electronic graphical display of a relationship between the one or more values of the calculated blood flow characteristic and the identified one or more changes in geometry of the anatomic model.

The present invention provides methods for treating vascular diseases with hemogenic endothelial cells (HEs) obtained in vitro from pluripotent stem cells. The present invention also provides compositions and methods of producing the HEs.

The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or phenyl; R2 is hydrogen, cyano, halogen, alkylsulfonyl, alkyl, cycloalkyl or alkoxy; R3, R4, R5, R6, R7 and R8 are independently hydrogen, halogen, alkyl or alkoxy; most groups being optionally substituted; with the proviso that at least one of R2, R3, R4 is H; X1, X2, X3, X4, X5 and X6 are independently N or C; with the proviso that in each ring maximal one X is N.

Quinazoline dione compounds are provided for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction. Diseases treated by the methods described herein include, but are not limited to, cardiomyopathy, hypertrophic cardiomyopathy (HCM), abnormal heart rhythms, aortic disease, Marfan syndrome, coronary artery disease, heart attack, heart failure, rheumatic heart disease, peripheral vascular disease, stroke, deep vein thrombosis, and pulmonary embolism.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The invention provides a pharmaceutical composition. The pharmaceutical composition is prepared from aspirin, atorvastatin, valsartan, hydrochlorothiazide, folic acid substances and pharmaceutically acceptable auxiliary materials. The pharmaceutical composition provided by the invention has the advantages that the pharmaceutical composition provided by the invention has a multi-target synergistic prevention effect on vascular diseases, especially cerebral embolism, that is, the composition not only can reduce blood pressure, blood fat and blood homocysteine level, but also has an effect of preventing thrombosis, and reduces the risk of cerebral apoplexy. In addition, the form of the pharmaceutical composition is beneficial to improving the medication compliance of patients.

The invention belongs to the field of pathologies affecting the central nervous system: in particular, severe cerebral pathologies, more particularly those restricted by the presence of the blood-brain barrier (BBB): gliomas, cerebral metastases, neurodegenerative diseases (e.g. Alzheimer's, Parkinson's or ALS), genetic diseases (Huntington's, myopathies, Leigh syndrome, Rett syndrome), but also to the field of cancers, musculoskeletal and immunological disorders, vascular diseases (thrombus) in numerous organs (e.g. liver, kidney or muscle) and in combination with numerous therapeutic approaches (e.g. chemotherapy, immunotherapy, targeted therapy or gene therapy). The invention relates to a microbubble comprising a fluorinated polymer or copolymer and a fluorinated gas, to the use thereof and also to the polymer or copolymer intermediate compounds.

The invention relates in particular to a device for monitoring a health risk of a patient. The device (400) comprises means (410) (e.g., a smartphone camera) for obtaining visual information (430) (e.g., a video sequence) relating to the skin (420) of the patient, and means (430) for detecting an anomaly on the skin of the patient based at least in part on the obtained visual information, and means (440) for assigning a score value (445) to the detected anomaly, wherein the score value is associated with a health risk of the patient. The score value may help diagnose or predict peripheral vascular disease.